2022 ESMO| Professor Tong Zhongsheng: Good safety, better liver safety, Darcily may be the preferred first-line treatment for HR+/HER2-advanced breast cancer

*For medical professionals only

Interim analysis of the DAWNA-2 study showed that Darcily was safe and reliable, and adverse reactions were easy to manage

Management: Pay attention to changes in liver function, regular monitoring of blood routines

Choice: How to choose the appropriate CDK4/6 inhibitor to prolong survival time and improve quality of life are two important goals of advanced breast cancer treatment, and the risk-benefit ratio is comprehensively assessed when selecting specific drugs, so that patients can balance survival and quality of life [4
].

In terms of drug safety, whether adverse reactions will affect the implementation of treatment options will be considered comprehensively; Secondly, the characteristics of Chinese HR+/HER2-advanced breast cancer patients are different from those of foreign patients, for example, a certain proportion of patients with hepatitis B virus infection or gastrointestinal stress syndrome, the effect of
drugs on liver function and gastrointestinal function will also be considered when selecting CDK4/6 inhibitors.
On how to choose the right CDK4/6 inhibitor, Professor Tong Zhongsheng also shared his views: "In addition to drug safety, the most important thing is to look at the clinical efficacy of the drug, and whether it can provide long-term survival for patients is a very important factor
.

Compared with other CDK4/6 inhibitors, Darcily's second-line indications were approved late, but its excellent performance has also attracted industry attention
.

At the ESMO conference, the DAWNA-2 study data is also amazing, and it is the first CDK4/6 inhibitor
with a new ORR record for PFS exceeding 30 months in combination with AI first-line treatment.

Judging from the current research progress, the first-line and second-line treatment effects of Darcily are comparable to other CDK4/6 inhibitors, but have unique liver safety advantages, low perceptible side effects, and more advantages in clinical applications
.

Finally, Professor Tong Zhongsheng emphasized, "
As a pathogenic CDK4/6 inhibitor with unique mechanism, it has significant benefits in the first-line treatment of HR+/HER2-advanced breast cancer in China, easy management of hematologic adverse reactions, weaker liver toxicity, low perceptible side effects, or can be the first-line treatment of HR+/HER2-advanced breast cancer.
"

We are confident in domestic CDK4/6 inhibitors and look forward to continuing to validate the clinical effects
of Darcyly in first- and second-line treatments in real-world studies after marketing.
"
"
Expert Profile
Professor Tong Zhongsheng

• Vice President of Binhai Hospital, Cancer Hospital of Tianjin Medical University
• Chief Physician of the Department of Breast Oncology, Tianjin Medical University Cancer Hospital
• Member of the Standing Committee of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association
• Member of the Standing Committee of the Targeted Therapy Professional Committee of the Chinese Anti-Cancer Association
• Vice Chairman of the Breast Cancer Professional Group of the Geriatric Tumor Committee of the Chinese Geriatric Association
• Chairman of clinical chemotherapy professional committee of Tianjin Anti-Cancer Association
• Member of oncology Branch of Tianjin Medical Association
• He is a member of the editorial board of Chinese Oncology Clinic, Tianjin Medicine, Chinese Journal of Breast Diseases, And China Comprehensive Clinical

References:[1]Xu B, Zhang Q, Zhang P, et al.
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer:a randomized,phase 3 trial.
Nat Med.
2021 Nov; 27(11):1904-1909.
[2] Binghe Xu,Qingyuan Zhang,Pin Zhang,et al.
Dalpiciclib plus letrozole or anastrozole as 1st-line treatment for HR+/HER2-advanced breast cancer(DAWNA-2):a phase 3 trial.
2022 ESMO.
LBA16.
[3] Li N,Zhong QQ,Yang XR,et al.
Prognostic Value of Hepatitis B Virus Infection in Very Young Patients With Curatively Resected Breast Cancer:Analyses From an Endemic Area in China.
Front Oncol.
2020 Aug 7; 10:1403.
[4] Breast Cancer Expert Committee of National Center for Cancer Quality Control, Clinical Research Committee of Cancer Drugs of Chinese Anti-Cancer Association.
Consensus on the clinical application of CDK4/6 inhibitors in the treatment of hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer[J].
Chinese Journal of Oncology,2021,43(04):405-413.

*This article is only used to provide scientific information to medical personnel and does not represent the views of this platform